Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27036786 | 0.90 | MAPT (0.44) | NR1H2MAPTPARP1TNKS2PARP2 | |
| SCHEMBL17380692 | 0.89 | NR1H2 (0.41) | NR1H2MAPTPARP1TNKS2PARP2 | |
| SCHEMBL29191201 | 0.88 | ADORA1 (0.46) | NR1H2MAPTPARP1TNKS2PARP2 | |
| SCHEMBL30684052 | 0.87 | HPGD (0.43) | MAPTHPGDSALDH1A1 | |
| SCHEMBL22675497 | 0.86 | ADORA1 (0.46) | NR1H2MAPTPARP1TNKS2PARP2 | |
| SCHEMBL23685510 | 0.85 | NR1H2 (0.41) | NR1H2MAPTPARP1TNKS2PARP2 | |
| SCHEMBL28881468 | 0.82 | MAPT (0.46) | NR1H2MAPTPARP1TNKS2PARP2 | |
| SCHEMBL23632994 | 0.82 | MAPT (0.43) | NR1H2MAPTPARP1TNKS2PARP2 | |
| SCHEMBL27036602 | 0.82 | MAPT (0.38) | NR1H2MAPTPARP1TNKS2PARP2 | |
| SCHEMBL17949105 | 0.81 | MAPT (0.42) | NR1H2MAPTPARP1TNKS2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552811-B2 | Immunosuppressant, and preparation method therefor and use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| US-20260035388-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2026-02-05 | — | — | US | disclosed |
| US-12473282-B2 | Biphenyl fluorine double bond derivative, preparation method therefor, and pharmaceutical application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250084104-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2025-03-13 | — | — | US | disclosed |
| EP-4520328-A2 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2025-03-12 | — | — | EP | disclosed |
| US-12247038-B2 | Pyrido[3,2-d]pyrimidine compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-03-11 | — | — | US | disclosed |
| US-12187743-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4219492-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2024-11-27 | — | — | EP | disclosed |
| WO-2018119266-A1 | BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180177870-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20180177870-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| WO-2017222976-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170362253-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-12-21 | — | — | US | disclosed |
| US-20170362253-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-12-21 | — | — | US | disclosed |
| US-20170362253-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179202-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | NR1H2 278/4885MAPT 4685/4885PARP1 3187/4885 |
| US-20250084104-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | NR1H2 278/4885MAPT 4685/4885PARP1 3187/4885 |
| US-12552811-B2 | Immunosuppressant, and preparation method therefor and use thereof | CD274, PDCD1, PDCD1LG2 | NR1H2 197/4885MAPT 4689/4885PARP1 1738/4885 |
| US-12247038-B2 | Pyrido[3,2-d]pyrimidine compounds as immunomodulators | PDCD1, CD274, PDCD1LG2 | NR1H2 2403/4885MAPT 2355/4885PARP1 386/4885 |
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | CD274, PDCD1LG2, PDCD1 | NR1H2 495/4885MAPT 4007/4885PARP1 3395/4885 |
| US-12466822-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | NR1H2 278/4885MAPT 4685/4885PARP1 3187/4885 |
| US-20260035388-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | IL2, IL4, NFATC1 | NR1H2 1303/4885MAPT 4654/4885PARP1 2902/4885 |
| US-12473282-B2 | Biphenyl fluorine double bond derivative, preparation method therefor, and pharmaceutical application thereof | PDCD1, CD274, PDCD1LG2 | NR1H2 433/4885MAPT 2758/4885PARP1 511/4885 |
| US-12187743-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | NR1H2 278/4885MAPT 4685/4885PARP1 3187/4885 |
| US-20180177870-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | CD274, PDCD1LG2, PDCD1 | NR1H2 495/4885MAPT 4007/4885PARP1 3395/4885 |
| US-20170362253-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | NR1H2 278/4885MAPT 4685/4885PARP1 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.